Cargando…

Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report

INTRODUCTION: Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jui-Hung, Tang, Wen-Hao, Lee, Chien-Hsing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164326/ https://www.ncbi.nlm.nih.gov/pubmed/25213589 http://dx.doi.org/10.1186/1752-1947-8-304

Ejemplares similares

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022)

PSUN124 Weight Loss from Combination Anti-Obesity Medications Including Glucagon-Like Peptide-1 Receptors Agonists can Approach that Achieved from Bariatric Surgery
por: Bomberg, Eric M, et al.
Publicado: (2022)

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
por: Ard, Jamy, et al.
Publicado: (2021)

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
por: Michos, Erin D., et al.
Publicado: (2023)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis
por: Vosoughi, Kia, et al.
Publicado: (2021)

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
por: Jensen, Anders Boisen, et al.
Publicado: (2023)

What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
por: Klair, Nimra, et al.
Publicado: (2023)

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
por: Lin, Yuan, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 receptor agonists, weight loss, and gastric emptying: have I gut news for you
por: Jalleh, Ryan J., et al.
Publicado: (2022)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
por: Monami, Matteo, et al.
Publicado: (2012)

Weight Loss after Bariatric Surgery in Morbidly Obese Adolescents with MC4R mutations
por: Censani, Marisa, et al.
Publicado: (2013)

Changes in plasma aldosterone level after weight loss by bariatric surgery in morbidly obese patients
por: Suwannasrisuk, Preaw, et al.
Publicado: (2020)

Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
por: Su, Haoran, et al.
Publicado: (2008)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
por: Zhao, Li, et al.
Publicado: (2018)

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis
por: Yeh, Tzu-Lin, et al.
Publicado: (2023)

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment
por: Ali, Muzaffar, et al.
Publicado: (2021)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists
por: Ahmed, Sana, et al.
Publicado: (2023)

Cushing's Syndrome in a Morbidly Obese Patient Undergoing Evaluation before Bariatric Surgery
por: Borsoi, Livia, et al.
Publicado: (2014)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery
por: Preda, Veronica, et al.
Publicado: (2023)

SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation
por: Klee, Philippe, et al.
Publicado: (2020)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Sun, Feng, et al.
Publicado: (2015)

Weight Loss After Bariatric Surgery Reverses Insulin-Induced Increases in Brain Glucose Metabolism of the Morbidly Obese
por: Tuulari, Jetro J., et al.
Publicado: (2013)

Effect of Weight Loss after Bariatric Surgery on Thyroid-Stimulating Hormone Levels in Euthyroid Patients with Morbid Obesity
por: Juiz-Valiña, Paula, et al.
Publicado: (2019)

The relationship between specialized pro-resolving lipid mediators, morbid obesity and weight loss after bariatric surgery
por: Schulte, Fabian, et al.
Publicado: (2020)

Central Resistance to Thyroid Hormones in Morbidly Obese Subjects Is Reversed after Bariatric Surgery-Induced Weight Loss
por: Juiz-Valiña, Paula, et al.
Publicado: (2020)

Management of Laryngotracheal Stenosis in Obesity. Is This Another Co-morbidity that Can Be Improved with Weight Loss Following Bariatric Surgery?
por: Fehervari, Matyas, et al.
Publicado: (2021)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
por: Salehi, Marzieh, et al.
Publicado: (2014)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_blvkuv6203jcei23dvq2ne5n7e